|
‘It’s never too late to get fit’
Wausau Daily Herald People who are obese or out of shape in their 40s or 50s might think it’s too late to start getting fit, but new research finds that shaping up in middle age lowers the odds for heart failure later in life. What’s more, the reduction in risk is … |
Salaam to the quintessential Indian at heart – Russia & India Report (blog)
|
Salaam to the quintessential Indian at heart
Russia & India Report (blog) This was the kind of Hindi that very few people in India’s financial could speak. At the end of his speech, there was a standing ovation that lasted a few minutes. The ambassador completely won the hearts of everyone in that crowd who had no clue he’d … |
Commonly used catheters double blood clot risk in ICU and cancer patients – Newstrack India
Commonly used catheters double blood clot risk in ICU and cancer patientsNewstrack IndiaThis was found in a new University of Michigan Health System study including an Indian origin scientist. In recent years, PICCs have become the preferred device thr…
Actress Hackforth-Jones loved by all – The Australian
Brisbane TimesActress Hackforth-Jones loved by allThe AustralianFour months ago Hackforth-Jones was diagnosed with lung cancer. Not long after she began writing a blog. The last entry, according to Fairfax media, was titled AbFab in India, followed by …
Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to … – SYS-CON Media (press release)
|
Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to …
SYS-CON Media (press release) HORSHOLM, Denmark, May 20, 2013 /PRNewswire/ — Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney … |
Final STRATO Clinical Study Data Demonstrates Potential For LCP-Tacro™ To … – Daily Markets (press release)
|
Final STRATO Clinical Study Data Demonstrates Potential For LCP-Tacro™ To …
Daily Markets (press release) HORSHOLM, Denmark, May 20, 2013 /PRNewswire/ – Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney … |
Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to … – PR Newswire (press release)
|
Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to …
PR Newswire (press release) HORSHOLM, Denmark, May 20, 2013 /PRNewswire/ — Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney … |
Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to … – GlobeNewswire (press release)
|
Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to …
GlobeNewswire (press release) An example of this are hand tremors, that are both common and often affect the patient’s quality of life,” said Anthony Langone, M.D., Associate Professor at Vanderbilt University and Medical Director of Renal Transplantation, Nashville Veteran Affairs … |
German Federal Joint Committee (G-BA) Issues Final Assessment Report for … – Sacramento Bee
|
German Federal Joint Committee (G-BA) Issues Final Assessment Report for …
Sacramento Bee The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
German Federal Joint Committee (G-BA) Issues Final Assessment Report For … – Daily Markets (press release)
|
German Federal Joint Committee (G-BA) Issues Final Assessment Report For …
Daily Markets (press release) The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |